Tuesday, 12 April 2016 10:31

Glaxo’s Potential Cure for “Bubble Boy Disease” One Step Closer

Written by 
Rate this item
(1 Vote)

Glaxo’s Potential Cure for “Bubble Boy Disease” One Step Closer

A potential cure for children born with a form of an extremely rare immune-system condition often referred to as “bubble-boy disease” has moved a step closer to approval after receiving the support of a European Union regulatory panel.


The treatment, which involves inserting a new gene into the patient’s stem cells, received a positive opinion from the European Medicines Agency’s advisory committee on Friday, paving the way for final approval in coming months.

It is aimed at children with a disease known as ADA-SCID, a rare condition in which a single genetic defect prevents sufferers from developing a robust immune system, leaving them very susceptible to infections. Without treatment, they rarely live for more than two years.

Currently, the best available option is a bone-marrow transplant, but success heavily depends on how well matched the donor is. For the one in four babies who have a well matched family member, a transplant can be an effective cure. But for the rest, success rates can be as low as 50%, according to Bobby Gaspar,professor of pediatrics and immunology at London’s Great Ormond Street Hospital.

The new therapy, called Strimvelis, was developed by a group of scientists and doctors based in Milan who have used it to treat 22 children over the past 14 years. All are still alive, most without needing any further treatment. In 2010, GlaxoSmithKline PLC struck a licensing deal for the rights to market the therapy.

If approved, it would be only the second gene therapy to be sold in Europe, after UniQure NV’s Glybera for a rare genetic condition in which the body can’t break down fat molecules. No gene therapies are approved for sale in the U.S.

The ADA-SCID gene therapy has moved at a cautious pace. Scientists tested an older form of gene therapy in children with the disease as early as 1990, but suffered a setback when, around 10 years later, several of those patients developed a leukemia-like condition.

“To be recognized as a licensed medicine shows gene therapy has come a long way forward,” Dr. Gaspar said.

One complication of administering Strimvelis: For now, it can be performed only in the Milan hospital where it was developed. The procedure involves removing some stem cells from the patient, applying the gene therapy outside the body and then reinjecting them, all of which must be done in quick succession to keep within the short “shelf life” of stem cells.

Parents will probably be willing to take their babies to Milan for treatment if it is considered the best option: Children from as far away as the U.S. and the Middle East came to Italy to take part in the clinical trial, according to Martin Andrews, head of the company’s rare-disease unit. Still, Glaxo aims to eventually make the therapy available in several “hubs,” and is working on methods to increase the shelf life of stem cells so that the procedure could be done remotely, by sending the child’s stem cells to a central facility for the gene therapy, he said. Glaxo also plans to seek approval from America’s Food and Drug Administration in 2017.

While Strimvelis is unlikely to move the needle for Glaxo in terms of revenue—around 14 babies are born with the condition every year in Europe—the company is betting that the technology can be used as the basis for several new treatments, Mr. Andrews said.

Rare diseases have drawn increasing interest from drugmakers in the past few years because the industry can command high prices for effective treatments in diseases with few other available therapies.

“If efficacy is demonstrated, payers are willing to reimburse [the companies],” said Mladen Tomich, head analyst for rare diseases at health-care consultancy Decision Resources Group. “While the price tag is high the overall expenditures are still limited due to the small patient population.”

Mr. Andrews didn’t disclose Glaxo’s pricing plans for the treatment but said it was considering flexible pricing models, including amortizing the payment over several years.



Read 574406 times Last modified on Tuesday, 12 April 2016 10:52


  • Comment Link Tiffany Monday, 11 December 2017 16:48 posted by Tiffany

    online casino no deposit bonus
    free casino slot games
    casino free games
    free casino games download

  • Comment Link Ramona Monday, 11 December 2017 16:40 posted by Ramona

    Wonderful goods from you, man. I have understand
    your stuff previous to and you're just extremely excellent.
    I really like what you've acquired here, really like what you're stating and the way in which you say it.
    You make it enjoyable and you still take care of to keep it sensible.
    I can not wait to read much more from you. This is really a wonderful web site.

  • Comment Link Claudio Monday, 11 December 2017 16:33 posted by Claudio

    It's genuinely very difficult in this active life to listen news on Television, so I
    just use internet for that reason, and get the hottest information.

  • Comment Link Finlay Monday, 11 December 2017 16:27 posted by Finlay

    I'm pretty pleased to find this web site. I want to to thank you for ones time
    for this wonderful read!! I definitely savored every part of it and i also have you
    book marked to look at new things on your web site.

  • Comment Link Ilene Monday, 11 December 2017 16:22 posted by Ilene

    I constantly emailed this website post page to all my associates,
    since if like to read it then my contacts will

  • Comment Link https://www.yelp.com site Monday, 11 December 2017 16:17 posted by https://www.yelp.com site

    Excellent way of describing, and pleasant post
    to get data concerning my presentation topic, which i am going to convey in school.

  • Comment Link Nannette Monday, 11 December 2017 16:13 posted by Nannette

    buy cialis levitra viagra
    top rated canadian pharmacies online
    buy levitra uk

  • Comment Link Layne Monday, 11 December 2017 16:10 posted by Layne

    I wanted to make an effort to express my gratitude towards this wonderful
    blog and you! Loving it!

  • Comment Link Dorthea Monday, 11 December 2017 15:53 posted by Dorthea

    Thanks a bunch for sharing this with all folks you really understand what
    you're talking about! Bookmarked. Kindly also talk over with my site =).
    We will have a link exchange contract between us

  • Comment Link Maggie Monday, 11 December 2017 15:40 posted by Maggie

    Just beneficial information is provided by this web site and that I
    am subscribing to it this instant! Thank you folks!

Leave a comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.